Business Description
DMK Pharmaceuticals Corp
NAICS : 325412
SIC : 2834
ISIN : US00547W3079
Description
DMK Pharmaceuticals Corp Formerly Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19.
Financial Strength
| Name | Current | Vs Industry | Vs History |
|---|
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 53.2 | |||||
9-Day RSI | 32.29 | |||||
14-Day RSI | 32.41 | |||||
12-1 Month Momentum % | 900 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History |
|---|
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
FCF Margin % | -261.52 | |||||
OCF Margin % | -259.01 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
EV-to-Forward-EBIT | -0.13 | |||||
EV-to-Forward-Revenue | 0.4 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:DMKPQ
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
DMK Pharmaceuticals Corp Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 3.62 | ||
| EPS (TTM) ($) | -9.58 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | 0.85 | ||
| 3-Year Sortino Ratio | 5.68 | ||
| Volatility % | 1448.19 | ||
| 14-Day RSI | 32.41 | ||
| 14-Day ATR ($) | 0.000009 | ||
| 20-Day SMA ($) | 0.0001 | ||
| 12-1 Month Momentum % | 900 | ||
| 52-Week Range ($) | 0.00001 - 0.001 | ||
| Shares Outstanding (Mil) | 10.09 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 0 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
DMK Pharmaceuticals Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
DMK Pharmaceuticals Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-16 | In 142 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-14 | In 48 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 48 days | ||
| First quarter earnings conference call for 2026 | 2026-05-22 | 0.00 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-22 | 0.00 (+0.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-04-13 17:00 | 0.00 (+0.00%) | ||
| Annual report for 2025 | 2026-04-13 | 0.00 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-04-13 | 0.00 (+0.00%) | ||
| Annual report for 2025 | 2026-03-16 | 0.00 (+0.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-23 17:00 | 0.00 (+0.00%) |
Show
Entries
DMK Pharmaceuticals Corp Frequently Asked Questions
What is DMK Pharmaceuticals Corp(DMKPQ)'s stock price today?
The current price of DMKPQ is $0.00. The 52 week high of DMKPQ is $0.00 and 52 week low is $0.00.
When is next earnings date of DMK Pharmaceuticals Corp(DMKPQ)?
The next earnings date of DMK Pharmaceuticals Corp(DMKPQ) is 2026-08-14 Est..
Does DMK Pharmaceuticals Corp(DMKPQ) pay dividends? If so, how much?
DMK Pharmaceuticals Corp(DMKPQ) does not pay dividend.
Guru Commentaries on OTCPK:DMKPQ
No articles.
Press Release
Articles on DMK Pharmaceuticals Corp
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers